These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17123403)

  • 1. Urgent inhibitor issues: targets for expanded research.
    Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():107-13. PubMed ID: 17123403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of inhibitors.
    Reipert B; Arruda V; Lillicrap D
    Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
    Leissinger CA
    Am J Hematol; 2012 May; 87 Suppl 1():S23-6. PubMed ID: 22473571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat inhibitors in haemophilia.
    Makris M; Hay CR; Gringeri A; D'Oiron R
    Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M; Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?
    Di Minno G; Coppola A
    Haemophilia; 2013 Jan; 19 Suppl 1():18-23. PubMed ID: 23278996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.